Zevra Therapeutics, Inc. (ZVRA)
11.65
-0.22
(-1.85%)
USD |
NASDAQ |
Aug 24, 16:00
11.66
+0.01
(+0.09%)
After-Hours: 20:00
Zevra Therapeutics Shareholders Equity (Quarterly) : 217.65M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 217.65M |
| March 31, 2026 | 205.80M |
| December 31, 2025 | 154.66M |
| September 30, 2025 | 133.16M |
| June 30, 2025 | 117.23M |
| March 31, 2025 | 41.02M |
| December 31, 2024 | 39.67M |
| September 30, 2024 | 69.77M |
| June 30, 2024 | 32.48M |
| March 31, 2024 | 48.82M |
| December 31, 2023 | 61.86M |
| September 30, 2023 | 67.47M |
| June 30, 2023 | 68.50M |
| March 31, 2023 | 71.40M |
| December 31, 2022 | 75.12M |
| September 30, 2022 | 93.79M |
| June 30, 2022 | 99.23M |
| March 31, 2022 | 121.50M |
| December 31, 2021 | 127.12M |
| September 30, 2021 | 131.74M |
| June 30, 2021 | 130.66M |
| March 31, 2021 | 84.25M |
| December 31, 2020 | -66.41M |
| September 30, 2020 | -62.33M |
| Date | Value |
|---|---|
| June 30, 2020 | -62.86M |
| March 31, 2020 | -68.68M |
| December 31, 2019 | -74.46M |
| September 30, 2019 | -70.62M |
| June 30, 2019 | -81.55M |
| March 31, 2019 | -74.84M |
| December 31, 2018 | -66.57M |
| September 30, 2018 | -95.34M |
| June 30, 2018 | -83.54M |
| March 31, 2018 | -79.68M |
| December 31, 2017 | -57.52M |
| September 30, 2017 | -48.10M |
| June 30, 2017 | -39.28M |
| March 31, 2017 | -33.93M |
| December 31, 2016 | -18.70M |
| September 30, 2016 | -9.802M |
| June 30, 2016 | 0.333M |
| March 31, 2016 | -11.48M |
| December 31, 2015 | -10.12M |
| September 30, 2015 | -5.746M |
| June 30, 2015 | 3.463M |
| March 31, 2015 | -26.14M |
| December 31, 2014 | -48.51M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Innoviva, Inc. | 1.233B |
| Collegium Pharmaceutical, Inc. | 311.91M |
| Johnson & Johnson | 84.97B |
| Ligand Pharmaceuticals, Inc. | 967.52M |
| Harrow, Inc. | 15.20M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 302.71M |
| Total Liabilities (Quarterly) | 85.06M |
| Debt to Equity Ratio | 0.0069 |
| Current Ratio | 5.167 |
| Net Debt Paydown Yield | 1.42% |